Comment on: “Regorafenib: Start Low and Go Slow”-Reference-Cited by-同舟云学术

Comment on: “Regorafenib: Start Low and Go Slow”

Published:2015-12-04 Issue:1 Volume:11 Page:123-125
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

de la Fouchardière Christelle

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-015-0407-4.pdf

Reference14 articles.

1. Tabchi S, Ghosn M (2015) Regorafenib: start low and go slow. Target Oncol 10:445–7

2. Grothey A (2015) Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Clin Adv Hematol Oncol 13:514–7

3. Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–67

4. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M et al (2012) Regorafenib (BAY 73–4506) in advanced colorectal cancer: a phase I study. Br J Cancer 106:1722–7

5. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–12

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib in the treatment of metastatic colorectal cancer;Future Oncology;2018-09

2. Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow”;Targeted Oncology;2015-12-09